Tromsø, Norway, 2th February 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.2 million (40.5) and an EBITDA of NOK 1.3 million (20.8) for the fourth quarter of 2022. Highlights from Q4 and the full year 2022 ArcticZymes Technologies (AZT) had Q4 sales of NOK 28.2 million a reduction of 30% (Q4 2021: NOK 40.5 million) and sales …
ArcticZymes Technologies releases its first ESG report
Tromsø, Norway, 30st December 2022 – ArcticZymes Technologies ASA (OSE: AZT) releases its first comprehensive ESG report ArcticZymes Technologies has today released its first comprehnesive Environment, Social and Governane (ESG) report based on data for the year 2021. The report is prepared in accordance with the framework established by the Global Reporting Initiative (GRI) and the Sustainability Accounting Standards Board …
ArcticZymes Technologies launches SAN HQ 2.0 ELISA Kit
ArcticZymes Technologies is pleased to announce the launch of our newest product, the SAN HQ 2.0 ELISA kit. This classic sandwich ELISA is designed for the detection and quantification of SAN HQ 2.0 enzyme in samples taken from the manufacturing stages of a complex biomanufacturing process such as the production of viral vectors. The SAN HQ 2.0 ELISA Kit is …
ArcticZymes Technologies launches AZscriptâ„¢ Reverse Transcriptase
Tromsø, Norway, 16th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) launches AZscriptâ„¢ Reverse Transcriptase ArcticZymes Technologies (AZT) today announces the launch of its new product AZscriptâ„¢ Reverse Transcriptase (RT). Launching the AZscript™ RT product is a natural expansion of the Company’s molecular tools portfolio. Reverse transcriptases are critical enzymes for molecular diagnostics and are used to convert RNA into DNA …